MarketPeel
Insider Trading Intelligence
Pricing
…
CS

Corazon (corsee) D. Sanders

RARE
DIRECTOR · ULTRAGENYX PHARMACEUTICAL INC. · CIK 0001796536
FILING MIX · LIFETIME54%/46%
BUYS
14
SELLS
12
TOTAL VALUE
$3.03M
COMPANIES
2
ACTIVE SINCE
Jun 2021
HOLDINGS NOW
21,095
AVG SELL PX
$153.75
TRADE KIND
SHOWING 26 / 26
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
8 backtested trades · 8 horizons · 7 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Corazon (corsee) D. Sanders, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d8+87.50%-2.39%+1.47%-3.86%-3.75%—
14d8+75.00%-0.64%+2.26%-2.90%-5.14%—
30d8+62.50%-6.99%+2.82%-9.81%-9.83%—
60d8+75.00%-3.21%+3.13%-6.34%-8.31%—
90d8+50.00%+1.50%+3.50%-2.00%-0.79%—
180d8+62.50%-4.00%+9.39%-11.75%-11.50%—
1y8(3 pending)+100.00%-14.21%+20.90%-35.11%-35.39%—
2y8(4 pending)+100.00%-29.97%+39.89%-69.86%-67.62%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
RARE · 21,095 shares · as of Jun 15, 2026
05,77411,54817,32123,09520222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 14 buys / 12 sellsCOVERAGE · 21 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
2,000$25.05$50.1K21,095Jun 15, 2026Jun 15, 2026 ↗View →
ONC
BEONE MEDICINES LTD.
SALE
212$309.59$65.6K0May 22, 2026May 27, 2026 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
7,751——23,095May 14, 2026May 18, 2026 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
14,058——14,058May 14, 2026May 18, 2026 ↗View →
ONC
BEONE MEDICINES LTD.
PURCHASE
2,627$159.03$417.8K2,627Nov 26, 2025Dec 1, 2025 ↗View →
ONC
BEONE MEDICINES LTD.
SALE
804$342.47$275.3K0Nov 26, 2025Dec 1, 2025 ↗View →
ONC
BEONE MEDICINES LTD.
SALE
34,151——0Nov 26, 2025Dec 1, 2025 ↗View →
ONC
BEONE MEDICINES LTD.
SALE
1,823$340.20$620.2K804Nov 26, 2025Dec 1, 2025 ↗View →
ONC
BEONE MEDICINES LTD.
SALE
2,665$337.00$898.1K0Sep 5, 2025Sep 9, 2025 ↗View →
ONC
BEONE MEDICINES LTD.
PURCHASE
2,665$155.68$414.9K2,665Sep 5, 2025Sep 9, 2025 ↗View →
ONC
BEONE MEDICINES LTD.
SALE
34,645——0Sep 5, 2025Sep 9, 2025 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE10b5-1
10b5-1 plan
2,405$37.39$89.9K15,344Jun 20, 2025Jun 23, 2025 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
10,787——10,787May 15, 2025May 19, 2025 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
5,740——17,749May 15, 2025May 19, 2025 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE10b5-1
10b5-1 plan
584$40.98$23.9K12,009Jul 2, 2024Jul 3, 2024 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
9,900——9,900Jun 18, 2024Jun 20, 2024 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
5,345——12,593Jun 18, 2024Jun 20, 2024 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE10b5-1
10b5-1 plan
1,737$41.10$71.4K7,248Jun 10, 2024Jun 10, 2024 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
585$46.76$27.4K8,985Jun 30, 2023Jun 30, 2023 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
SALE
1,485$51.65$76.7K9,570Jun 8, 2023Jun 9, 2023 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
7,110——7,110Jun 7, 2023Jun 9, 2023 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
3,860——11,055Jun 7, 2023Jun 9, 2023 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
3,300——7,195Jun 24, 2022Jun 29, 2022 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
6,245——6,245Jun 24, 2022Jun 29, 2022 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
3,895——3,895Jun 29, 2021Jun 30, 2021 ↗View →
RARE
ULTRAGENYX PHARMACEUTICAL INC.
PURCHASEGRANT
Stock grant
7,255——7,255Jun 29, 2021Jun 30, 2021 ↗View →
Other insiders · RARE
Loading peer insiders…
About this filer
CIK 0001796536
ROLE
Director
PRIMARY
RARE
COMPANIES
2
ACTIVE SINCE
Jun 2021
MARKETPEEL · /INSIDER/0001796536DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback